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the patients fulfilled the maximal test criteria. Distinct dis-
ease-specific exercise response patterns as well as treatable 
co-pathologies were observed. The validity of response pat-
terns was better in case of a maximal test.  Conclusion: An 
MOB-enhanced 6MWT is feasible within daily routine and 
safe in patients with various diseases. It does not negatively 
affect WD. MOB is a valuable tool to identify factors limiting 
exercise in patients irrespective of their underlying disease. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Walking tests have been used for many years to assess 
overall performance status of patients with different un-
derlying diseases  [1, 2] . The 6-min walk test (6MWT) has 
been extensively investigated and correlates well with im-
pairment in activities of daily life  [3] . It is currently used 
as an indicator when to put patients on a lung transplan-
tation list  [4, 5] , for the assessment and follow-up of pa-
tients with various pulmonary diseases  [6, 7] and for the 
evaluation of functional outcomes after pulmonary end-
arterectomy  [8] . The walking distance (WD) during the 
6MWT correlates with baseline cardiac output and peak 
 Key Words 
 Cardiopulmonary exercise testing   Six-minute walk test   
Mobile cardiopulmonary monitoring   Oxygen uptake   
Submaximal exercise 
 Abstract 
 Background: The 6-min walk test (6MWT) is frequently used 
to assess overall cardiopulmonary fitness and to predict out-
come, but it yields little diagnostic information. Portable 
telemetric devices allow performing the 6MWT with real-
time cardiopulmonary monitoring.  Objectives: The study 
was designed to analyze feasibility, safety and clinical useful-
ness of a mobile cardiopulmonary monitoring (MOB)-en-
hanced 6MWT.  Methods: From August 2003 to June 2007, 
261 consecutive patients with chronic lung and/or heart dis-
ease as well as healthy controls underwent MOB-enhanced 
6MWTs. A subgroup of 33 individuals had the test done with 
and without cardiopulmonary monitoring on independent 
days.  Results: No test-related adverse events occurred 
throughout the study. Whether the 6MWT was done with-
out or with cardiopulmonary monitoring (n = 33) did not sig-
nificantly influence the walking distance (WD: 528  8 183 vs.
525  8 192 m; nonsignificant). Fifty-nine percent (155/261) of 
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oxygen uptake (V O 2 peak ) during a maximal cardiopulmo-
nary exercise test  [9] . In patients with pulmonary arterial 
hypertension (PAH), advanced heart failure and idio-
pathic pulmonary fibrosis, the 6MWT helps to predict 
mortality  [10–12] . However, the 6MWT yields only little 
information about the underlying cause of exercise limi-
tation.
 Classic symptom-limited cardiopulmonary exercise 
testing (CPET) is used to measure exercise capacity in 
patients with respiratory or cardiac diseases, to monitor 
treatment response and to investigate unexplained dys-
pnea  [13, 14] . V O 2 peak is a strong predictor of survival in 
patients with primary pulmonary hypertension and an 
indicator for operability of pulmonary patients  [15–17] . 
The symptom-limited CPET requires more resources 
than the 6MWT, but carries the advantage of providing 
important information in order to differentiate between 
a broad variety of underlying diseases.
 The combination of a 6MWT with a real-time telemet-
ric mobile cardiopulmonary monitoring (MOB) poten-
tially adds the diagnostic power of classic CPET to the 
safe and time-saving procedure of the 6MWT  [18] . MOB 
might be a superior prognostic and follow-up test com-
pared to conventional 6MWT in patients with various 
potentially co-existing exercise-limiting diseases. In a 
previous study, we were able to demonstrate that MOB is 
feasible and safe in healthy individuals  [18] . In this study, 
we evaluate the feasibility and safety of MOB in clinical 
routine in a larger cohort of patients with various under-
lying diseases and different degrees of exercise limitation. 
In order to exclude an impact of wearing MOB equipment 
on WD, conventional 6MWT and MOB were performed 
in randomized order on 2 consecutive days.
 Patients and Methods 
 Study Design 
 The study was conducted at the University Hospital Basel, 
Switzerland. We included 261 consecutive patients referred to our 
lung function laboratory for a 6MWT between August 2003 and 
June 2007 to assess the feasibility, safety and diagnostic yield of 
MOB in clinical routine. Exclusion criteria were inability to walk, 
conditions preventing the use of a face mask (e.g. an anatomic face 
anomaly, panic disorder or claustrophobia), need for oxygen sup-
ply during walking and any acute coronary event during the pre-
vious month. The consistency of WD measured during conven-
tional 6MWT and MOB was validated in a subset of patients in 
order to assess potential side effects of the MOB equipment. Twen-
ty-one patients scheduled for a 6MWT and 12 healthy controls 
were recruited. 6MWT was performed with and without MOB 
equipment in randomized order on 2 consecutive days. Patients 
who had not performed a 6MWT in the previous 6 months and 
controls had a practice test first. Patients were excluded from the 
study if they had a resting S p O 2  ! 85% while breathing room air. 
Informed consent was obtained from all participants, and the lo-
cal ethics committee approved the study.
 Six-Minute Walk Test  
 A 6MWT with pulse oxymetry was performed on an indoor 
walking course of 30 m according to the American Thoracic So-
ciety (ATS) guidelines  [19] . At the end of the test, WD, Borg dys-
pnea, fatigue level and subjective reasons for exercise limitation 
were recorded. The 6MWT was supervised by an experienced 
lung function technician.
 6MWT with MOB Device 
 The MOB device (Oxycon Mobile  ; Viasys Healthcare, USA) 
consists of an ECG-triggered belt (Polar  Electro OY T-61) or a 
three-lead electrocardiograph to monitor heart rate, an oxygen 
sensor for the fingertip to monitor transcutaneous oxygen satura-
tion (S p O 2 ), a facemask with a dead space  ! 30 ml and a flow sensor 
to measure breathing frequency and tidal volumes, a sensor unit 
containing the oxygen-measuring cell and the carbon dioxide an-
alyzer, a data storage unit and a data transfer unit with integrated 
long-range telemetry, allowing real-time monitoring of the data 
on a laptop computer. The weight of the portable equipment is
950 g, including belt, battery and mask ( fig. 1 ). In order to estimate 
the maximal voluntary ventilation, the first step after installation 
of the MOB device was to measure forced vital capacity and forced 
expiratory volume in the 1st s (FEV 1 ). Spirometry was followed by 
a resting phase until oxygen consumption (V O 2 ) and ventilation 
reached a steady state. The ensuing 6MWT was performed ac-
cording to ATS guidelines  [19] and followed by a recovery phase 
of 4–6 min. WD, Borg dyspnea, fatigue level and the subjective 
reason for limitation were recorded. MOB was supervised by an 
experienced lung function technician and a physician.
 In order to determine the test intensity during MOB, sugges-
tions made by the ATS for CPET were applied  [20] . The effort was 
considered maximal if either one or more of the following criteria 
were fulfilled: (1) maximal heart rate  6 90% of predicted; (2) 
V O 2 peak  1 84% of predicted, and (3) ventilatory reserve  ! 11 liters 
or  ! 15%. V O 2 peak was assessed during the last 15 s of the 6MWT. 
Minimal S p O 2 during MOB was recorded. V O 2 instabilities due to 
discontinuation of the 6MWT were not analyzed. Lung function 
parameters were interpreted according to ATS standards. Stan-
dard equations were used to calculate ventilatory reserve [1 –
(V E max /maximal voluntary ventilation)], maximal predicted val-
ues for V O 2 [(60 – 0.55  ! age) for males and (48 – 0.37  ! age) for 
females] and maximal predicted heart rate (220 – age)  [21, 22] .
 Statistical Analysis 
 Data were analyzed using R (version 2.9.0). Results are ex-
pressed as medians (range) or means  8 SD as appropriate. Com-
parisons between different disease categories were done using 
analysis of variance for parametric variables and   2 tests for differ-
ences between proportions. Spearman’s rank correlation was cal-
culated between V O 2 and WD. Agreement between conventional 
and MOB 6-min walk distance (6MWD) was tested using the 
Bland-Altman and linear regression analysis. Individual response 
patterns to exercise were analyzed using principal component 
analysis. Principal component analysis summarizes multivariate 
information into a small set of orthogonal vectors (principal com-
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ponents) which extract the main sources of variation present in the 
dataset. Individual classification of patients into predefined diag-
nostic categories was assessed by between-group analysis (BGA) 
 [23] , a supervised counterpart of the principal component analysis.
 Results 
 WD of Conventional 6MWT Compared to MOB 
 Thirty-three individuals (21 patients and 12 healthy 
controls) performed both 6MWT and MOB on consecu-
tive days in random order ( table 1 ). No significant differ-
ence in the WD between 6MWT and MOB was found 
(mean WD during 6MWT 528  8 183 m vs. mean WD 
during MOB 525  8 192 m; nonsignificant). Sixteen of the 
33 participants had a longer WD during 6MWT com-
pared to MOB, 16 performed better during MOB and 1 
individual walked exactly the same distance in both tests. 
The test order – first 6MWT or MOB – did not signifi-
cantly influence WD. Bland-Altman analysis showed 
good agreement between MOB and conventional WDs 
with a bias of 3 m (95% confidence interval: –6 to 12) and 
a precision of 26 m ( fig. 2 ). Regression analysis gave a lin-
ear model with a slope of 1.04  8 0.02 and an intercept of 
–25.8  8 13.3 and shows an excellent goodness of fit (re-
sidual SE = 24.6, R 2 = 0.98;  fig. 2 ).
 Feasibility and Safety of MOB 
 Two-hundred forty-four patients and 17 controls per-
formed an enhanced 6MWT with MOB. Although 131 of 
the 244 (54%) patients were severely impaired, with a 
baseline FEV 1  ! 50% (n = 54; 22%), a WD  ! 300 m (n = 46; 
19%) or both (n = 28; 11%), no adverse events (syncope, 
chest pain, arrhythmia, prolonged hypoxemia or bron-
chospasm) occurred. Technical problems occurred in 11 
of 261 (4%) tests: evaluation of heart rate, FEV 1 and satu-
ration were not possible in 4, 1 and 6 tests, respectively.
 Fig. 1. MOB-enhanced 6MWT. The test is 
performed on an indoor 30-meter track 
and conducted according to ATS recom-
mendations. The patient is wearing the 
950-gram equipment including a face 
mask. 
Table 1. D emographics and exercise parameters of patients and 
healthy controls performing both 6MWT and MOB on separate 
days in random test order
Patients
(n = 21)
Healthy
controls
(n = 12)
Sex, males/females 13/8 5/7
Age, years 57814 32810
Disease category, n
Restrictive lung disease 6
Obstructive lung diseases 7
Pulmonary hypertension 6
Cardiac disease 2
Body mass index 26.686.5 23.482.8
FEV1, % predicted 83829 10389
MOB WD, m 420 (180–566) 732 (668–904)
MOB Borg 5.182.6 4.982.1
6MWT WD, m 440 (219–560) 740 (642–870)
6MWT Borg 4.282.3 4.381.6
Difference in WD, m 23815 19813
% of WD 5.984.6 2.581.8
M eans 8 SD and medians (ranges).
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 Diagnostic Yield of MOB 
 Although 6MWT is generally considered to be associ-
ated with submaximal effort, 155 of the 261 (59%) MOB 
tests reached criteria for maximal effort as specified 
above. Twenty-three (9%) subjects reached a heart rate 
 1 90% of the predicted maximal heart rate, 36 (14%) sub-
jects had V O 2 peak  6 84% predicted and 97 (37%) subjects 
reached ventilatory limits with either ventilatory reserve 
 ! 11 liters or  ! 15%. Twenty-four of the 155 subjects (15%) 
fulfilled more than one criterion for maximal exercise.
 The underlying cause of exercise limitation could be 
identified in 124 (48%) tests. Eighty-six (33%) patients 
had a ventilatory limitation, 27 (10%) had a cardiocircula-
tory limitation and 11 (4%) had an isolated decrease in 
S p O 2  ! 80%. In half of the patients (n = 38; 51%) with se-
verely impaired WD  ! 300 m (n = 74), the underlying 
cause of exercise limitation could be identified. In most 
of the tests, limitation corresponded to the underlying 
disease ( table 2 ). In several patients, the cause of exercise 
limitation did not correspond with the underlying dis-
ease leading to the identification of potentially treatable 
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 Fig. 2. WD measured during MOB and conventional 6MWT did 
not differ.  a Bland-Altman difference plot. –––– = systematic bias 
( d–) and the limits of agreement ( d– 8 2  SD ).  b Linear regression 
plot. Both the line of best fit (––––) and the identity line (· · · · ·)
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 Fig. 3. Observed exercise limitations according to disease catego-
ries. The bar plots ( a ) show the percentage of patients with limita-
tions in each disease category. Exercise limitation did not follow 
the pretest expectation in all cases, leading to the detection of pre-
viously unknown co-morbidities. b Individual details are given in 
the Venn diagram. The numbers in the lower right corner indicate 
the number of patients without any limitation. 
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co-morbidities. Some patients reached more than one cri-
terion for maximal exercise ( fig. 3 ). The disease-specific 
profiles of patients are presented in  figure 4 .  Figure 4 a 
displays 10 randomly chosen patients with maximal ex-
ercise test criteria from each disease group (‘training set’). 
The first BGA axis discriminates healthy controls and 
cardiac disease patients from the three other groups. Car-
diac patients and healthy controls had nearly identical 
response patterns, being in line with the fact that cardio-
vascular limitation is physiological. The second BGA axis 
discriminates between patients with pulmonary hyper-
tension and patients with chronic obstructive pulmonary 
disease (COPD)/restrictive lung disease. The classifica-
tion accuracy of the other patients having reached criteria 
for maximal exercise (‘test set’) was 85%.  Figure 4 b shows 
that 9 patients were misclassified, including 7 COPD pa-
tients tending to be classified as pulmonary hypertension 
patients. Overall, WD during MOB correlated signifi-
cantly with V O 2 peak in the total population (r = 0.82, p  ! 
0.001), as well as within the different disease categories. 
Patients with COPD had a shorter WD for comparable 
V O 2 than other patients ( fig. 5 ).
 Discussion 
 The results of this study show that the use of a telemet-
ric MOB during a conventional 6MWT is feasible in clin-
ical routine, safe even in severely impaired patients and 
of higher diagnostic value than the 6MWT alone.
 In our study, MOB equipment and software proved to 
be reliable. Minor technical problems occurred in only 
4% of the tests and consisted mostly of artifacts in the 
readings of heart rate or S p O 2 . In most cases, sufficient 
information for the interpretation of MOB was available. 
Since pulse oxymetry showed significant desaturation in 
most patients and even in most healthy controls, S p O 2 
seemed to be of limited value. We were able to show that 
wearing mobile CPET equipment does not influence the 
6MWD, thus enabling the comparison of WD measured 
by MOB and conventional 6MWT. Importantly, no seri-
ous adverse event occurred during MOB. It proved to be 
as safe as the conventional 6MWT even in severely im-
paired patients. MOB however is more time consuming 
than the conventional 6MWT. Overall, it took roughly 30 
min for a technician to complete a test, about 10–15 min 
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more than for a conventional 6MWT. Previous studies 
showed that telemetric measurement of metabolic and 
ventilatory data is feasible and safe in healthy individuals 
 [18, 21] . Telemetric systems were used to analyze cardio-
respiratory adaptations during 6MWT, and reliability 
and intensity of the 6MWT in patients with chronic heart 
failure  [24, 25] , COPD  [26, 27] and PAH  [28] . Different 
authors described a correlation between the 6MWD and 
V O 2 measured during CPET on a cycle ergometer in pa-
tients with COPD  [29] , chronic heart failure and pulmo-
nary hypertension  [9, 10] . In these studies, the correlation 
coefficient between the WD and V O 2  peak ranged from 
0.48 for patients with PAH to 0.73 for patients with COPD. 
The present study is the first to investigate the correlation 
between simultaneously measured WD and V O 2 during 
a 6MWT in a larger cohort of patients with varying un-
derlying diseases. We found a correlation coefficient of 
0.82 for the simultaneous measurement of WD and 
V O 2 peak during MOB.
 6MWT is generally considered to be a submaximal 
test  [21] . However, in our study, 59% of the participants 
met the criteria of maximal effort. There are other reports 
that conclude that the 6MWT might be a maximal test
in patients with heart failure  [24] and COPD  [30, 31] . 
Troosters et al.  [27] compared the physiological respons-
es to exercise during an encouraged 6MWT and an incre-
mental cycle CPET in patients with COPD. A similar 
V O 2 peak was found for both tests, but a V O 2 plateau was 
typically reached after the 3rd min during the 6MWT.
 Therefore, the 6MWT is believed to better assess 
steady-state exercise performance compared to incre-
mental cycle CPET. A plateau of V O 2 might better re-
flect the integrated physiologic response to exercise
and, therefore, explain the high prognostic value of the 
6MWT.
 We observed disease-specific patterns of response to 
exercise. Patients with pulmonary hypertension had a 
particularly low V O 2 peak and a low S p O 2 , possibly due to 
the pronounced impairment in diffusion leading to hy-
poxemia, with increased dead space ventilation due to 
pulmonary vascular obliteration and an insufficient rise 
in cardiac output during exercise due to excessively high 
pulmonary vascular resistance  [32] . In contrast, patients 
with COPD had a relatively high V O 2 peak at a similar WD. 
Probably, the reduced WD in these patients might be ex-
plained by the systemic nature of COPD with skeletal 
muscle involvement  [33, 34] and/or a more pronounced 
physical deconditioning.
 The present study also demonstrates that MOB com-
pared to conventional 6MWT leads to additional diag-
nostic information, such as overall fitness and the cause 
of exercise limitation irrespective of the underlying dis-
Table 2. Demographics and exercise responses during MOB (means 8 SD)
Controls Restrictive
lung disease
(n = 45)
Obstructive
lung disease
(n = 106)
PAH
(n = 64)
Heart disease
(n = 29)
All subjects
(n = 261)
Sex, males/females 9/8 23/22 61/45 24/40 17/12 127/134
Age, years 37812 62812 62814 61814 7089 61815
Body mass index 2484 2987 2586 2786 3188 2787
FEV1, % predicteda 107811 72822 49821 76827 92823 68829
VO2, ml/kg/min 3286 1583 1584 1383 1483 1586
VO2 peak, % predicteda 95816 66819 60817 58818 66814 63819
n >84% 11 (65%) 7 (16%) 11 (10%) 5 (8%) 2 (7%) 36 (14%)
WD, ma 720881 3898106 3408123 3398118 348894 3748147
n <300 m 0 7 (16%) 33 (31%) 25 (39%) 9 (31%) 74 (28%)
Ventilatory reserve, %a 47817 31819 21819 35818 48814 31821
n <15% or <11 liters 1 (6%) 14 (31%) 66 (62%) 15 (23%) 1 (3%) 97 (37%)
 Maximal heart rate, % predictedb 85811 71812 69813 72816 70813 71814
n >90% 6 (35%) 2 (4%) 4 (4%) 8 (13%) 3 (10%) 23 (9%)
Minimal SpO2, %c 9185 8787 8786 8487 9283 8787
n <80% 0 8 (18%) 12 (11%) 14 (22%) 0 34 (13%)
a  Missing values, n = 1; b missing values, n = 4; c missing values, n = 6.
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ease. For example, we could identify cardiac limitation 
due to exercise-induced arrhythmia in patients with re-
strictive lung disease or ventilatory limitation in patients 
with pulmonary vascular disease or chronic heart dis-
ease. In these patients, MOB had a significant impact on 
their management. In addition, as depicted in  figure 4 , we 
could detect COPD patients with potentially underlying/
associated PAH using MOB, since they showed exercise 
characteristics of both disease groups. Holverda et al.  [35] 
described a large overlap in exercise test characteristics of 
COPD patients with and without associated pulmonary 
hypertension and concluded that in addition to a low ven-
tilatory efficiency, a low resting S p O 2 and accentuated de-
crease during exercise suggest the presence of PAH in 
COPD patients.
 Further, the WD of a conventional 6MWT might vary 
due to physiologic changes, but also due to varying com-
pliance of the patient. During MOB, the patients’ compli-
ance and exercise quality can be assessed simultaneously 
by measuring heart rate, ventilatory reserves and S p O 2 
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